|
Joe Dervan, Ph.D. Vice President of Research and Development
Dr. Dervan has more than 20 years of biopharmaceutical drug-development expertise, from bench to commercialization, including development of a broad range of immuno-oncology therapeutics. He is a graduate of Sheffield University Medical School, UK, where he obtained his Ph.D., in Molecular Medicine, researching protein-DNA interactions, and publishing his work in the Proceedings of the National Academy of Sciences USA and Nature Structural and Molecular Biology.
He went on to undertake postdoctoral work within the department
of Molecular Biophysics & Biochemistry at Yale University and completed an MBA
at Warwick University Business School, UK. Dr. Dervan started his pharmaceutical
career at Pfizer, UK where he performed bioanalysis of a range of corticosteroids and
related prodrugs. He also worked within the field of proteomics utilizing the world’s
first genome sequences at F. Hoffmann-La Roche, Basel, Switzerland. Following his
postdoc, he worked at Protalex, Inc, as Director of Protein Chemistry and
Biopharmaceutical Manufacturing where he oversaw laboratory operations,
drug substance and drug product development, and manufacturing operations.
Following his time at Protalex, Inc, Dr. Dervan worked as a senior consultant for
several biotech companies. Prior to joining PDS Biotech, he held leadership roles at
GSK where he lead multiple analytical lifecycle management project teams, supporting
global development of a broad range of mid-late phase biopharmaceutical assets.
|